David E. Wheadon - 30 Apr 2026 Form 3 Insider Report for Seaport Therapeutics, Inc. (SPTX)

Reporting relationship: Director
Issuer ticker: SPTX
Reported as of: 30 Apr 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 30 Apr 2026, 20:10:25 UTC
Prior SEC filing: 28 Jan 2026
Next SEC filing: 14 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Lana Gladstein, Attorney-in-Fact

Key filing fact

David E. Wheadon filed Form 3 for Seaport Therapeutics, Inc. (SPTX) on 30 Apr 2026.

Key facts

This page summarizes David E. Wheadon's Form 3 filing for Seaport Therapeutics, Inc. (SPTX).
0 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 30 Apr 2026, 20:10.

Change

Previous filing in this sequence was filed on 28 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001789507 Primary reporting owner

Wheadon David E.

Relationship: Director
Address: SEAPORT THERAPEUTICS, INC., 101 SEAPORT BLVD., FLOOR 12, BOSTON
Signature: /s/ Lana Gladstein, Attorney-in-Fact
Signature date: 30 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPTX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 30 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 77,042
Exercise price: $3.05
Footnotes: F1

SPTX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 30 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,258
Exercise price: $10.30
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

1/3rd of the shares underlying this option vested and became exercisable on August 12, 2025, with the remaining shares vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Footnote F2

The shares underlying this option shall vest and become exercisable on February 24, 2027, subject to the Reporting Person's continued service on such vesting date.

SEC remarks

Exhibit 24 - Power of Attorney